Ninety-three patients with colorectal cancer who developed moderate-to-severe COM ( WHO grade @ ) during any cycle of chemotherapy using FOLFOX , FOLFIRI , and/or XELOX treatment were randomly assigned to receive either TJ-@ ( n = @ ) or placebo ( n = @ ) .